Profile picture

Associate Professor Brendon Neuen

The George Institute for Global Health, Sydney (Australia)
Membership: ESC Professional Member
Follow
Biography
Dr Brendon Neuen is a Nephrologist and Director of the Kidney Trials Unit at Royal North Shore Hospital, and Senior Research Fellow at The George Institute for Global Health in Sydney, Australia. He is widely recognised for his expertise in cardio-renal-metabolic medicine and is involved in the leadership of several large-scale trials evaluating therapeutic strategies to slow CKD progression and reduce cardiovascular risk. Dr Neuen established the SGLT2 Meta-Analysis Cardio-Renal Trialists' Consortium, bringing together data on >90,000 patients to better understand the effects of this class of medicines in different types of patients. His work has directly informed more than 25 major international and national guidelines, position papers and scientific statements which define optimal care for people with type 2 diabetes and kidney disease including the KDIGO guidelines and American Diabetes Association Standards of Care.
Logo ESC

Contributor content

Global assessment of cardiovascular risk prediction tools: Analysis of over 10 million individuals from international cohorts and trials
Presentation
Global assessment of cardiovascular risk prediction tools: Analysis of over 10 million individuals from international cohorts and trials
Bidirectional relationship between kidney disease progression and cardiovascular events in type 2 diabetes: new Insights from the CANVAS Program and CREDENCE trial
Presentation
Bidirectional relationship between kidney disease progression and cardiovascular events in type 2 diabetes: new Insights from the CANVAS Program and CREDENCE trial
Natriuretic peptides, kidney function and clinical outcomes in heart failure with mildly reduced or preserved ejection fraction: pooled data from the I-PRESERVE, TOPCAT, PARAGON and DELIVER trials
Presentation
Natriuretic peptides, kidney function and clinical outcomes in heart failure with mildly reduced or preserved ejection fraction: pooled data from the I-PRESERVE, TOPCAT, PARAGON and DELIVER trials
Effects of canagliflozin on hyperkalaemia and serum potassium in people with diabetes and chronic kidney disease: Insights from the CREDENCE trial
Presentation
Effects of canagliflozin on hyperkalaemia and serum potassium in people with diabetes and chronic kidney disease: Insights from the CREDENCE trial

ESC 365 is supported by